Registry of Lobbyists

Registration - In-house Corporation

Hoffmann-La Roche Limited / BRIGITTE NOLET, PRESIDENT AND CHIEF EXECUTIVE OFFICER

Registration Information

In-house Corporation name: Hoffmann-La Roche Limited
Previous in-house corporation names
Responsible Officer Name: BRIGITTE NOLET, PRESIDENT AND CHIEF EXECUTIVE OFFICER 
Responsible Officer Change History
Initial registration start date: 2001-01-18
Registration status: Active
Registration Number: 952745-64

Associated Communications

Total Number of Communication Reports: 426

Monthly communication reports in the last 6 months: 15

Version 9 of 62 (2008-06-20 to 2008-08-13)

Version 9 of 62 (2008-06-20 to 2008-08-13) was submitted prior to the Lobbying Act coming into force on July 2, 2008. Due to different information requirements at that time, the registration is presented in the following format.

A. Information about Responsible Officer and Corporation

Corporation: Hoffmann-La Roche Limited
2455 Meadowpine Blvd.
Mississauga, ON  L5N 6L7
Canada
Telephone number: 905-542-5555
Fax number: 905-542-7130  
Responsible officer name and position during the period of this registration: RONNIE MILLER, PRESIDENT AND CEO  
Description of activities: Hoffmann-La Roche Limited deals with the healthcare system in the prevention, screening, diagnosis, treatment and management of acute and long-term disease and supports leading research and development - including clinical research, clinical trials and genetic research.
 
The client is a subsidiary of the following parent companies: F. Hoffmann-La Roche AG
Grenzacherstrasse 124
4070 Basle
Switzerland

Coalition The corporation is not a member of a coalition.
Subsidiary: The corporation does not have any subsidiaries that could be affected by the outcome of the undertaking.
Other direct interests The corporation's activities are not controlled or directed by another individual, organization or corporation with a direct interest in the outcome of this undertaking.
 
Was the corporation funded in whole or in part by any domestic or foreign government institution in the last completed financial year? No
 

B. Lobbyists Employed by the Corporation

Name: Michèle Beaubien
Position title: Executive Director, Government and Corporate Affairs
Public offices held: No
 
Name: Lorenzo Biondi
Position title: Vice President, Medical & Regulatory Affairs
Public offices held: No
 
Name: Ciro Caravaggio
Position title: VP, Oncology, Hematology & Rheumatology Business Units
Public offices held: No
 
Name: Jean-Guy Cyr
Position title: National Manager, Health Policy and Government Relations
Public offices held: No
 
Name: Linnea Doyle
Position title: Director of Market Access
Public offices held: No
 
Name: James Hall
Position title: VP, Urgent Care, Transplant, Virology & AVA Business Units
Public offices held: No
 
Name: Nabil Henein
Position title: Director, Regulatory Affairs
Public offices held: No
 
Name: Jamie Slater
Position title: Product Manager
Public offices held: No
 
Name: Ilona Torontali
Position title: Vice President, Public Affairs
Public offices held: No
 
Name: Bridget Wells
Position title: Director of Health Policy and Government Relations
Public offices held: No
 
Name: James Willoughby
Position title: Vice President, General Counsel & Corporate Secretary
Public offices held: No
 

C. Lobbying Activity Information

Federal departments or organizations which have been or will be communicated with during the course of the undertaking: Aboriginal Affairs and Northern Development Canada, Agriculture and Agri-Food Canada (AAFC), Atlantic Canada Opportunities Agency (ACOA), Canadian International Development Agency (CIDA), Canadian International Trade Tribunal (CITT), Canadian Space Agency (CSA), Canadian Transportation Agency (CTA), Citizenship and Immigration Canada, Competition Tribunal (CT), Correctional Service of Canada (CSC), Environment Canada, Federal Office of Regional Development – Quebec (FORD[Q]), Finance Canada (FIN), Foreign Affairs and International Trade Canada (DFAITC), Health Canada (HC), Human Resources Development Canada (HRDC), Industry Canada, Justice Canada (JC), Members of the House of Commons, National Defence (DND), National Research Council (NRC), Natural Resources Canada (NRCan), Natural Sciences and Engineering Research Council (NSERC), Office of the Auditor General, Office of the Information and Privacy Commissioner (OIPC), Patented Medicine Prices Review Board (PMPRB), Prime Minister's Office (PMO), Privy Council Office (PCO), Public Safety and Emergency Preparedness Canada (PSEPC), Public Service Commission of Canada (PSC), Public Works and Government Services Canada, Revenue Canada (RC), Royal Canadian Mounted Police (RCMP), Senate of Canada, Service Canada (ServCan), Solicitor General Canada (SGC), Statistics Canada (StatCan), Transport Canada (TC), Treasury Board Of Canada Secretariat (TBS), Veterans Affairs Canada (VAC), Western Economic Diversification Canada (WD)
Communication techniques that have been used or are expected to be used in the course of the undertaking:
Meetings, Presentations, Telephone calls, Written communications, whether in hard copy or electronic format
 
Subject Matter: Areas of Concern: Aboriginal Affairs, Agriculture, Constitutional Issues, Consumer Issues, Defence, Education, Employment and Training, Energy, Environment, Financial Institutions, Fisheries, Forestry, Government Procurement, Health, Immigration, Industry, Infrastructure, Intellectual Property, Internal Trade, International Relations, International Trade, Justice and Law Enforcement, Labour, Regional Development, Science and Technology, Small Business, Sports, Taxation and Finance, Transportation
 
Subject Matter: Retrospective: Treasury Board: Smart Regulations, pandemic planning. Industry Canada: Science and Technology Strategy, Patent Medicine Notice of Compliance regulations, Medical Devices regulations, Patent Act, pharmaceutical and biotechnology Research and Development issues, smart regulations, patent policy, life sciences industry, international aid programs. Health Canada: drug safety, data protection regulations, innovation issues, drug approval, pandemic planning, international aid programs, national pharmaceutical strategy, biotechnology, smart regulations, Food and Drugs Act, in vitro device medical device safety, in vitro device medical device approval, Progressive Licensing Framework, review process, Canada's Access to Medicines Regime, Subsequent Entry Biologics, Risk communications to Canada from manufacturers, health professionals and consumers, to the public via Health Canada and manufacturers, and Product Monographs, Food and Consumer Safety Action Plan, Clinical trials regulations and registrations, Post Notice of Compliance Change Guidance: Quality, Access to Information, and International Memorandum of Understandings. Foreign Affairs/Trade: ongoing international issues, patent issues, access and benefit sharing issues, international aid programs. Finance: Budget and budget update. CIDA: international aid programs.
Subject Matter: Prospective: Treasury Board: Smart Regulations, pandemic planning. Industry Canada: Science and Technology Strategy, Patent Medicine Notice of Compliance regulations, Medical Devices regulations, Patent Act, pharmaceutical and biotechnology Research and Development issues, smart regulations, patent policy, life sciences industry, international aid programs. Health Canada: drug safety, data protection regulations, innovation issues, drug approval, pandemic planning, international aid programs, national pharmaceutical strategy, biotechnology, smart regulations, Food and Drugs Act, in vitro device medical device safety, in vitro device medical device approval, Progressive Licensing Framework, review process, Canada's Access to Medicines Regime, Subsequent Entry Biologics, Risk communications to Canada from manufacturers, health professionals and consumers, to the public via Health Canada and manufacturers, and Product Monographs, Food and Consumer Safety Action Plan, Clinical trials regulations and registrations, Post Notice of Compliance Change Guidance: Quality, Access to Information, and International Memorandum of Understandings. Foreign Affairs/Trade: ongoing international issues, patent issues, access and benefit sharing issues, international aid programs. Finance: Budget and budget update. CIDA: international aid programs.
 

Details Regarding the Identified Subject Matter

Categories Description
Policy or Program access and benefit sharing issues
Policy or Program Access to Information
Policy or Program biotechnology
Bill or Resolution, Policy or Program Budget and Budget Update
Policy or Program Canada's Access to Medicines Regime
Policy or Program Clinical trials regulations and registrations
Regulation data protection regulations
Policy or Program drug approval
Policy or Program drug safety
Policy or Program Food and Consumer Safety Action Plan
Policy or Program, Bill or Resolution Food and Drugs Act
Policy or Program Health Canada International Memorandum of Understandings
Policy or Program Health Canada Post Notice of Compliance Change Guidance: Quality
Policy or Program Health Canada review process
Policy or Program Health Canada Risk communications to Canada from manufacturers, health professionals and consumers, to the public via Health Canada and manufacturers, and Product Monographs
Policy or Program innovation issues
Policy or Program international aid programs
Policy or Program international pharmaceutical issues
Policy or Program in vitro device medical device approval
Policy or Program in vitro device medical device safety
Policy or Program lifesciences trends
Regulation Medical Devices Regulations
Policy or Program national pharmaceutical strategy
Policy or Program pandemic planning
Bill or Resolution Patent Act
Policy or Program Patented Medicine Prices Review Board Pricing Guidelines
Policy or Program patent policy
Policy or Program pharmaceutical and biotechnology R&D issues
Regulation PM (NOC) regulations
Policy or Program Progressive Licensing Framework
Policy or Program Science and Technology Strategy
Policy or Program smart regulations
Policy or Program, Regulation Subsequent Entry Biologics
Regulation User Fees Act: Cost Recovery

Government institutions added through a communication report: Public Safety Canada (PS) View